Physician profile
Brian D Clements
NPI 1346329778
$5,007.33
in general payments reported to CMS, 2019-2025
38 companies · $819 in 2025
The $819 reported for 2025 was more than what 82% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $917 · 2020: $199 · 2021: $761 · 2022: $647 · 2023: $791 · 2024: $874 · 2025: $819.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,483.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,483.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $609.69 | 2021-2025 | Vraylar, Qulipta, Viberzi |
| Pfizer INC. | $593.76 | 2019-2025 | |
| Novo Nordisk INC | $552.09 | 2019-2025 | Wegovy, Ozempic, Saxenda |
| Glaxosmithkline, LLC. | $530.71 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals Lp | $397.90 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Lilly USA, LLC | $305.62 | 2019-2025 | Mounjaro, Zepbound, Kisunla |
| Sumitomo Pharma America, INC. | $225.88 | 2023-2025 | Gemtesa |
| Merck Sharp & Dohme LLC | $174.79 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Esperion Therapeutics, INC. | $145.34 | 2020-2021 | |
| Sanofi-Aventis U.S. LLC | $139.46 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $128.03 | 2019-2025 | Jardiance, Ofev |
| Dexcom, INC. | $98.08 | 2024-2025 | Dexcom G6 Transmitter |
| Bayer Healthcare Pharmaceuticals INC. | $97.23 | 2021-2024 | |
| Janssen Pharmaceuticals, INC | $90.18 | 2019-2021 | |
| Exact Sciences Corporation | $83.34 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Clements listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.